Scarica l'app Stockscreener
103.22
1.37%
1.40
Dopo l'orario di chiusura:
103.22
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$101.82
Aprire:
$102.16
Volume 24 ore:
1.25M
Relative Volume:
0.60
Capitalizzazione di mercato:
$20.45B
Reddito:
$7.68B
Utile/perdita netta:
$903.80M
Rapporto P/E:
23.20
EPS:
4.45
Flusso di cassa netto:
$1.14B
1 W Prestazione:
+13.24%
1M Prestazione:
+10.05%
6M Prestazione:
+3.31%
1 anno Prestazione:
-5.57%
Intervallo 1D:
$101.75
$103.57
Intervallo di 1 settimana:
$95.00
$103.57
Portata 52W:
$89.24
$116.71
Zimmer Biomet Holdings Inc Stock (ZBH) Company Profile
Nome
Zimmer Biomet Holdings Inc
Settore
Industria
Telefono
(574) 267-6131
Indirizzo
345 EAST MAIN STREET, WARSAW, IN
Confronta ZBH con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ZBH
Zimmer Biomet Holdings Inc
|
103.22 | 19.81B | 7.68B | 903.80M | 1.14B | 4.45 |
|
ABT
Abbott Laboratories
|
129.40 | 228.63B | 43.11B | 13.98B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
102.50 | 152.25B | 18.49B | 2.51B | 3.23B | 1.68 |
|
SYK
Stryker Corp
|
378.95 | 144.00B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.91 | 118.82B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.68 | 45.89B | 5.69B | 4.14B | 577.90M | 6.96 |
Zimmer Biomet Holdings Inc Stock (ZBH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-15 | Aggiornamento | Roth Capital | Neutral → Buy |
| 2024-12-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-09-10 | Iniziato | Wolfe Research | Peer Perform |
| 2024-07-01 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-05-30 | Iniziato | Goldman | Neutral |
| 2024-05-21 | Aggiornamento | Argus | Hold → Buy |
| 2024-01-04 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-10-20 | Iniziato | ROTH MKM | Neutral |
| 2023-08-28 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2023-05-03 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-04-11 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-03-31 | Aggiornamento | Jefferies | Underperform → Hold |
| 2023-03-29 | Iniziato | UBS | Sell |
| 2023-03-10 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-01-09 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-01-05 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-01-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-11-23 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2022-10-18 | Iniziato | Barclays | Underweight |
| 2022-10-12 | Iniziato | Jefferies | Underperform |
| 2022-05-27 | Downgrade | Needham | Buy → Hold |
| 2022-04-13 | Downgrade | Truist | Buy → Hold |
| 2022-04-01 | Downgrade | Citigroup | Buy → Neutral |
| 2022-03-02 | Ripresa | BofA Securities | Underperform |
| 2022-03-02 | Downgrade | Loop Capital | Buy → Hold |
| 2022-02-08 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2022-02-08 | Reiterato | Citigroup | Buy |
| 2022-02-08 | Reiterato | Deutsche Bank | Hold |
| 2022-02-08 | Reiterato | JMP Securities | Mkt Outperform |
| 2022-02-08 | Reiterato | JP Morgan | Neutral |
| 2022-02-08 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2022-02-08 | Reiterato | Stifel | Buy |
| 2022-02-08 | Reiterato | Truist | Buy |
| 2022-02-08 | Reiterato | UBS | Neutral |
| 2022-02-08 | Reiterato | Wells Fargo | Underweight |
| 2022-02-02 | Downgrade | UBS | Buy → Neutral |
| 2022-01-19 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2022-01-10 | Downgrade | Mizuho | Buy → Neutral |
| 2022-01-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-01-04 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2021-12-09 | Downgrade | Needham | Strong Buy → Buy |
| 2021-12-07 | Iniziato | Loop Capital | Buy |
| 2021-11-23 | Downgrade | Argus | Buy → Hold |
| 2021-09-14 | Ripresa | Raymond James | Mkt Perform |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-09 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2021-01-04 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-12-18 | Reiterato | Needham | Strong Buy |
| 2020-10-20 | Iniziato | Northland Capital | Market Perform |
| 2020-09-11 | Iniziato | Wolfe Research | Outperform |
| 2020-08-05 | Reiterato | Needham | Strong Buy |
| 2020-04-28 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-04-09 | Downgrade | Evercore ISI | Outperform → In-line |
| 2020-04-07 | Reiterato | Needham | Strong Buy |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Buy |
| 2020-01-08 | Iniziato | SunTrust | Buy |
| 2020-01-07 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2020-01-07 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2019-12-04 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2019-10-07 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2019-09-18 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2019-08-12 | Aggiornamento | Argus | Hold → Buy |
| 2019-07-30 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2019-07-29 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2019-06-11 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2019-04-24 | Aggiornamento | Needham | Buy → Strong Buy |
Mostra tutto
Zimmer Biomet Holdings Inc Borsa (ZBH) Ultime notizie
Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term - Yahoo Finance
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Q2 2025 Earnings Call Transcript - MSN
Is Zimmer Biomet Holdings Inc. stock forming a cup and handleHigh Conviction Technical Setups - classian.co.kr
Needham Maintains a Neutral Stance on Zimmer Biomet Holdings (ZBH) - MSN
Zimmer (ZBH) Builds Robotics Growth Pipeline, but BofA Sees Limited Near-Term Upside - MSN
Zimmer Biomet (ZBH) Jumps After Raising 2025 Outlook on Strong Hip and Knee Sales—Is Momentum Sustainable? - simplywall.st
Healthcare Sector Analysts Weigh In on Sangamo Biosciences, Pliant Therapeutics, and Zimmer Biomet Holdings - AInvest
What You Need To Know Ahead of Zimmer Biomet's Earnings Release - MSN
Zimmer Biomet Acquires Monogram Technologies, Boosting Robotics Growth Pipeline, but BofA Sees Limited Near-Term Upside - AInvest
A Quick Look at Today's Ratings for Zimmer Biomet Holdings(ZBH.US), With a Forecast Between $96 to $138 - 富途牛牛
While shareholders of Zimmer Biomet Holdings (NYSE:ZBH) are in the red over the last five years, underlying earnings have actually grown - simplywall.st
Zimmer Biomet Holdings Inc. stock outperforms competitors on strong trading day - MSN
Zimmer Biomet Holdings Maintains Hold Rating Amid Volatility Concerns - AInvest
Zimmer Biomet Surges Despite 404th-Ranked Liquidity as Earnings Outperform and UBS Maintains Sell Rating - AInvest
UBS Raises Price Target for Zimmer Biomet Holdings (ZBH) to $96 | ZBH Stock News - GuruFocus
RBC Capital Raises Zimmer Biomet PT to $115, Maintains Outperform Rating - AInvest
UBS maintains Sell rating, raises Zimmer Biomet PT to $96 from $91. - AInvest
Morgan Stanley Raises Price Target on Zimmer Biomet to $100 From $95 - MarketScreener
Raymond James maintains Outperform rating on Zimmer Biomet with new PT of $113. - AInvest
Zimmer Biomet Holdings, Inc. shares fall 1.09% intraday as brokerages adjust price targets and global growth concerns persist. - AInvest
RBC Raises Price Target on Zimmer Biomet Holdings to $115 From $112, Keeps Outperform Rating - MarketScreener
Zimmer Biomet price target raised to $113 from $104 at Raymond James - TipRanks
UBS Hikes Price Target on Zimmer Biomet to $96 From $91, Maintains Sell Rating - MarketScreener
Bernstein raises Zimmer Biomet stock price target to $105 on improving outlook - Investing.com Canada
A Quick Look at Today's Ratings for Zimmer Biomet Holdings(ZBH.US), With a Forecast Between $95 to $138 - 富途牛牛
Zimmer Biomet Boosts 2025 Outlook on Strong Portfolio Growth and Reduced Tariff Impacts - AInvest
Zimmer Biomet price target raised to $96 from $91 at UBS - TipRanks
Zimmer Biomet raises 2025 outlook amid strong portfolio growth - Yahoo Finance
Zimmer Biomet Holdings, Inc.'s (NYSE:ZBH) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum? - Yahoo Finance
Zimmer Biomet Holdings: Balancing Strong Segment Growth with US Knee Challenges – Hold Rating Maintained - TipRanks
Zimmer Biomet Q2 2025 net sales up 7% to USD 2.077B - Medical Buyer
Jefferies Adjusts Price Target on Zimmer Biomet to $110 From $103, Maintains Hold Rating - MarketScreener
Bernstein Adjusts Price Target on Zimmer Biomet to $105 From $100, Maintains Market Perform Rating - MarketScreener
JPMorgan Adjusts Price Target on Zimmer Biomet to $115 From $105, Maintains Overweight Rating - MarketScreener
Spinal Fusion Devices Market Outlook Report 2025-2029: Revenues to Grow by $2.9 Billion Driven by Rising Spinal Disorders, Technological Advances, and Increasing Device Launches - GlobeNewswire Inc.
Zimmer: Q2 Earnings Snapshot - Connecticut Post
Zimmer Biomet Reports Strong Q2 2025 Results - TipRanks
Zimmer Biomet Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Zimmer Biomet Surges 7.99% on Revised Earnings and Tariff Relief Ranks 287th in $420M Volume - AInvest
Zimmer Biomet Reports Q2 Earnings, Raises Full-Year Outlook - InkFreeNews.com
Zimmer Biomet Holdings: Hold Rating Maintained Amid Stable Growth and Second-Half Optimism - TipRanks
Zimmer Biomet raises annual profit forecast on strong demand for medical devices - WKZO
Zimmer Biomet Holdings: Hold Rating Maintained Amid Modest Growth and Market Shifts - TipRanks
Zimmer Biomet price target raised to $138 from $135 at Roth Capital - TipRanks
Zimmer Biomet Exceeds Q2 Expectations with 7% YoY Revenue Growth - AInvest
Zimmer Biomet (NYSE:ZBH) Exceeds Q2 Expectations, Stock Soars - Yahoo Finance
Zimmer Biomet raises annual profit forecast on lower tariff impact - MSN
ZBH Stock Gains On Q2 Earnings and Revenue Beat, '25 EPS View Up - The Globe and Mail
Zimmer Biomet Flexes Strong Q2, Raises 2025 OutlookZimmer Biomet Holdings (NYSE:ZBH) - Benzinga
Zimmer Biomet posts Q2 beats, raises EPS guidance - MassDevice
Transcript : Zimmer Biomet Holdings, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Zimmer Biomet Holdings Inc Azioni (ZBH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Zimmer Biomet Holdings Inc Azioni (ZBH) insider trading
0.31%
1.36%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):